OXB expanded its multi-year commercial supply agreement with Bristol Myers Squibb to manufacture lentiviral vectors for BMS’s CAR-T programs, marking a shift from clinical to commercial production.

Chris Holt of BMS highlighted OXB’s scalable, reliable manufacturing capacity as essential to meeting the growing commercial demand for CAR-T therapies.

OXB and BMS executives framed the contract as a milestone that provides dependable, scalable manufacturing capacity to support increasing commercial demand for CAR-T treatments.

Financial terms were not disclosed, but OXB expects the deal to generate meaningful multi-year revenue and support its medium-term financial guidance.

The collaboration agreement (CSA) is designed to deliver meaningful multi-year revenue and aligns with OXB’s medium-term guidance and strategy as a cell and gene therapy CDMO.

The initial term is five years with an option to extend, and commercial manufacturing is expected to begin in 2026.

The agreement is multi-year with a five-year initial term and includes an option to extend.

The collaboration began during the COVID-19 pandemic in 2020, underscoring OXB’s position as a leading cell and gene therapy CDMO with strong revenue visibility.

The deal expands Oxford Biomedica’s existing partnership with BMS, originally established in March 2020, and is expected to generate meaningful multi-year revenue.

OXB’s expansion strategy includes growing its production network, including the Durham facility acquisition and ongoing development of its Bedford AAV center of excellence.

The press release emphasizes OXB’s role as a global CDMO with extensive viral vector expertise and notes facilities across multiple countries.

The agreement supports Oxford Biomedica’s focus as a cell and gene therapy CDMO and improves long-term revenue visibility.